Akero Therapeutics (AKRO)

• Market cap: $2.05B
• 1 day: 3.31%
• 5 days: 1.52%
• 1 month: -4.24%
• 3 months: 4.49%
• 6 months: 34.71%
• Year to date: 24.96%
• 1 year: 36.09%
• 5 years: 43.54%
• 10 years: 60.15%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Employees: 60

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

21% more capital invested

Capital invested by funds: $1.73B [Q2] → $2.1B (+$371M) [Q3]

10% more funds holding

Funds holding: 153 [Q2] → 168 (+15) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

1.13% less ownership

Funds ownership: 106.38% [Q2] → 105.25% (-1.13%) [Q3]

16% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 58

54% less call options, than puts

Call options by funds: $8.49M | Put options by funds: $18.6M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 70% upside
• Avg. target: $58 96% upside
• High target: $65 122% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Jonathan Woo 100% 1-year accuracy 1 / 1 met price target	122% upside $65	Buy Initiated	18 Nov 2024
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target	70% upside $50	Buy Reiterated	18 Nov 2024